The MPN Research Foundation is proud to congratulate Gary Gilliland today on his appointment as Director of the Fred Hutchinson Cancer Research Center in Seattle. His focus will be on immunotherapeutic treatments. Dr. Gilliland was a long time grantee of the Foundation, and headed one of the labs that originally discovered the JAK2 mutation was a genetic marker for a large subset MPN patients.
In a Forbes article by Matthew Herper, Dr. Gilliland states “These immunotherapeutic treatments, they raise the hackles on the back of my neck. I’ve never seen anything like this.”
We are thrilled that Dr. Gilliland will be focusing on treatment that has potential benefits to MPN patients everywhere. Click here to read the full story.